, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (&#34; BioVaxys&#34; 或 &#34; 公司&#34;) 宣佈，繼其於 2025 年 2 月 13 日發佈的新聞稿後，其主要監管機構不列顛哥倫比亞省證券委員會（&#34; BCSC&#34;）已接受公司的申請，並已授予管理停止交易令（&#34; MCTO&#34;），根據國家政策 12-203 – 管理停止交易令（&#34; NP 12-203&#34;).
如之前所述，公司申請了 MCTO，因為預計其截至 2024 年 10 月 31 日的審計年度財務報表、相關管理討論與分析以及其 52-109FV1 表格的首席執行官和首席財務官年度認證（統稱為&#34; 所需文件&#34;）的提交將會有短期延遲。根據國家工具 51-102 - 持續披露義務，所需文件必須在 2025 年 2 月 28 日之前提交。
雖然正在盡一切努力盡快提交所需文件，但導致延遲的因素之一是最近於 2024 年 2 月 16 日完成的對前 IMV Inc.所有知識產權、免疫治療平台技術和臨牀階段資產的收購。此次收購涉及 120 項專利，審計師完成對這些專利的審查和評估所需的時間比預期更長。公司預計其審計師 Dale Matheson Carr-Hilton LaBonte LLP 將在 2025 年 3 月 30 日之前完成審計，所需文件將在此之後儘快完成。
在 MCTO 生效期間，公眾仍然可以自由交易公司的上市普通股。然而，MCTO 將禁止公司的首席執行官和首席財務官在所需文件未提交期間交易公司的證券。此外，公司在所需文件提交之前，將被禁止直接或間接向公司內部人士或員工發行或收購證券，直到所需文件提交併滿足所有持續披露要求，且 MCTO 被撤銷。
公司確認將遵守 NP 12-203 下的替代信息指引，通過發佈雙週的違約狀態報告（以新聞稿形式），直到所需文件提交併滿足所有持續披露要求，且 MCTO 被撤銷。公司還確認，截至本新聞稿發佈之日，未對其進行破產程序，並且沒有其他關於公司事務的重大信息未被普遍披露。
關於 BioVaxys Technology Corp.
BioVaxys Technology Corp.（www.biovaxys.com）是一家註冊於加拿大不列顛哥倫比亞省的生物製藥公司，致力於通過基於 DPX™免疫教育技術平台和 HapTenix© '新抗原'腫瘤細胞構建平台的創新免疫療法改善患者生活，治療癌症、傳染病、抗原脱敏及其他免疫學領域。公司的臨牀階段管道包括 maveropepimut-S，目前正在進行針對晚期復發難治性瀰漫大 B 細胞淋巴瘤（DLBCL）和鉑耐藥卵巢癌的二期臨牀開發，以及 BVX-0918，這是一種個性化免疫治療疫苗，使用其專有的 HapTenix© '新抗原'腫瘤細胞構建平台，預計將在西班牙進入一期臨牀試驗，治療難治性晚期卵巢癌。
公司還利用其腫瘤免疫學知識和在個性化免疫治療疫苗接種後創建的獨特 T 淋巴細胞庫及其他數據集，利用預測算法和其他技術識別新的可靶向腫瘤抗原。
BioVaxys 的普通股在加拿大證券交易所上市，股票代碼為&#34;BIOV&#34;，並在法蘭克福證券交易所（FRA: 5LB）和美國 OTC 市場（OTCQB 市場）交易。有關更多信息，請訪問 www.biovaxys.com，並在 X 和 LinkedIn 上與我們聯繫。
代表董事會
簽名 &#34; James Passin&#34;
James Passin，首席執行官
電話：+1 740 358 0555
關於前瞻性信息的警示聲明
本新聞稿包含某些&#34;前瞻性信息&#34;和&#34;前瞻性聲明&#34;（統稱為&#34; 前瞻性聲明&#34;），符合適用證券立法的定義。除歷史事實外，本文中包含的所有聲明，包括但不限於與所需文件在 2025 年 3 月 30 日之前提交以及公司遵守 NP 12-203 所述替代信息指引的能力相關的聲明，均為前瞻性聲明。前瞻性聲明通常但不總是通過諸如&#34;預計&#34;、&#34;預期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;估計&#34;、&#34;潛在&#34;、&#34;可能&#34;等詞語或聲明事件、條件或結果&#34;將&#34;、&#34;可能&#34;、&#34;可以&#34;或&#34;應該&#34;發生或實現來識別。不能保證這些聲明將被證明是準確的，實際結果和未來事件可能與這些前瞻性聲明中表達或暗示的結果有實質性差異。
這些前瞻性聲明反映了聲明發布時的信念、觀點和預測，並基於多個假設和估計，主要假設是 BioVaxys 將在疫苗的開發和測試中取得成功，儘管 BioVaxys 認為這些假設是合理的，但本質上仍然受到重大商業、經濟、競爭、政治和社會不確定性及偶發事件的影響。許多已知和未知的因素可能導致實際結果、表現或成就與這些前瞻性聲明所表達或暗示的結果、表現或成就存在重大差異，相關方已基於或與這些因素相關的許多假設和估計作出判斷。這些因素包括但不限於，公司可能無法在 2025 年 3 月 30 日之前提交所需文件的風險。BioVaxys 不承擔任何更新前瞻性聲明的義務，包括信念、觀點、預測或其他因素的變化，除非適用的證券法律要求。
加拿大證券交易所未審查、批准或否決本新聞稿的內容，並不對本稿的充分性或準確性承擔責任。
Logo: https://mma.prnewswire.com/media/2415135/5196269/BioVaxys_Technology_Corp_Logo.jpg
來源：BioVaxys Technology Corp.
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzAzJk5ld3NJdGVtSWQ9TE4zMjM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMDMxODE5UFJfTkVXU19VU1BSX19fX19MTjMyMzQ4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzAzJk5ld3NJdGVtSWQ9TE4zMjM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMDMxODE5UFJfTkVXU19VU1BSX19fX19MTjMyMzQ4"/>

IMVIF

BioVaxys Technology Corp. 已被不列顛哥倫比亞省證券委員會授予管理停止交易令（MCTO），原因是未能按時提交截至 2024 年 10 月 31 日的經審計年度財務報表。延遲的原因是最近從 IMV Inc. 收購了知識產權和臨牀資產。公司預計將在 2025 年 3 月 30 日前完成所需的文件提交。在 MCTO 生效期間，首席執行官和首席財務官被禁止交易公司的證券，但公眾仍可以繼續交易公司的股票

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (&#34; BioVaxys&#34; or &#34; Company&#34;) announces that, further to its news release dated February 13, 2025, its principal regulator, the British Columbia Securities Commission (the &#34; BCSC&#34;), has accepted the Company's application for, and has granted, a management cease trade order (the &#34; MCTO&#34;) under National Policy 12-203 – Management Cease Trade Orders (&#34; NP 12-203&#34;).
<div class="lb-trans">, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (&#34; BioVaxys&#34; 或 &#34; 公司&#34;) 宣佈，繼其於 2025 年 2 月 13 日發佈的新聞稿後，其主要監管機構不列顛哥倫比亞省證券委員會（&#34; BCSC&#34;）已接受公司的申請，並已授予管理停止交易令（&#34; MCTO&#34;），根據國家政策 12-203 – 管理停止交易令（&#34; NP 12-203&#34;).
</div>As previously announced, the Company applied for the MCTO as it anticipated a short-term delay in the filing of its audited annual financial statements for the year ended October 31, 2024, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the &#34; Required Filings&#34;). Under National Instrument 51-102 - Continuous Disclosure Obligations, the Required Filings were required to be made not later than February 28, 2025.
<div class="lb-trans">如之前所述，公司申請了 MCTO，因為預計其截至 2024 年 10 月 31 日的審計年度財務報表、相關管理討論與分析以及其 52-109FV1 表格的首席執行官和首席財務官年度認證（統稱為&#34; 所需文件&#34;）的提交將會有短期延遲。根據國家工具 51-102 - 持續披露義務，所需文件必須在 2025 年 2 月 28 日之前提交。
</div>While every effort is being made to make the Required Filings as soon as possible, one of the factors contributing to the delay is the recent acquisition of all intellectual property, immunotherapeutics platform Technology, and clinical stage assets of the former IMV Inc. completed on February 16, 2024. The purchase involved the acquisition of 120 patents, and it is taking longer than expected for the auditor to complete its review and valuation of the patents. The Company expects that its auditor, Dale Matheson Carr-Hilton LaBonte LLP, will be in a position to complete the audit by March 30, 2025, ‎with the Required Filings to be completed as soon as possible ‎thereafter.‎
<div class="lb-trans">雖然正在盡一切努力盡快提交所需文件，但導致延遲的因素之一是最近於 2024 年 2 月 16 日完成的對前 IMV Inc.所有知識產權、免疫治療平台技術和臨牀階段資產的收購。此次收購涉及 120 項專利，審計師完成對這些專利的審查和評估所需的時間比預期更長。公司預計其審計師 Dale Matheson Carr-Hilton LaBonte LLP 將在 2025 年 3 月 30 日之前完成審計，所需文件將在此之後儘快完成。
</div>While the MCTO is in effect, the general investing public will continue to be able to trade freely the Company's listed common shares. However, the MCTO will prohibit the Company's Chief Executive Officer and Chief Financial Officer from trading securities of the Company for so long as the Required Filings are not filed. Additionally, the Company will be prohibited from directly or indirectly issuing or acquiring securities from insiders or employees of the Company until such time as the Required Filings have been made and all continuous disclosure requirements have been met by the Company, and the MCTO has been revoked.
<div class="lb-trans">在 MCTO 生效期間，公眾仍然可以自由交易公司的上市普通股。然而，MCTO 將禁止公司的首席執行官和首席財務官在所需文件未提交期間交易公司的證券。此外，公司在所需文件提交之前，將被禁止直接或間接向公司內部人士或員工發行或收購證券，直到所需文件提交併滿足所有持續披露要求，且 MCTO 被撤銷。
</div>The Company confirms that it will comply with the alternative information guidelines set out under NP 12-203 by issuing bi-weekly default status reports, in the form of news releases, until such time as the Required Filings have been made and all continuous disclosure requirements have been met by the Company, and the MCTO has been revoked. The Company also confirms as of the date of this news release that there is no insolvency proceeding against it and there is no other material information concerning the affairs of the Company that has not been generally disclosed.
<div class="lb-trans">公司確認將遵守 NP 12-203 下的替代信息指引，通過發佈雙週的違約狀態報告（以新聞稿形式），直到所需文件提交併滿足所有持續披露要求，且 MCTO 被撤銷。公司還確認，截至本新聞稿發佈之日，未對其進行破產程序，並且沒有其他關於公司事務的重大信息未被普遍披露。
</div>About BioVaxys Technology Corp.
<div class="lb-trans">關於 BioVaxys Technology Corp.
</div>BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
<div class="lb-trans">BioVaxys Technology Corp.（www.biovaxys.com）是一家註冊於加拿大不列顛哥倫比亞省的生物製藥公司，致力於通過基於 DPX™免疫教育技術平台和 HapTenix© '新抗原'腫瘤細胞構建平台的創新免疫療法改善患者生活，治療癌症、傳染病、抗原脱敏及其他免疫學領域。公司的臨牀階段管道包括 maveropepimut-S，目前正在進行針對晚期復發難治性瀰漫大 B 細胞淋巴瘤（DLBCL）和鉑耐藥卵巢癌的二期臨牀開發，以及 BVX-0918，這是一種個性化免疫治療疫苗，使用其專有的 HapTenix© '新抗原'腫瘤細胞構建平台，預計將在西班牙進入一期臨牀試驗，治療難治性晚期卵巢癌。
</div>The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes &amp; other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.
<div class="lb-trans">公司還利用其腫瘤免疫學知識和在個性化免疫治療疫苗接種後創建的獨特 T 淋巴細胞庫及其他數據集，利用預測算法和其他技術識別新的可靶向腫瘤抗原。
</div>BioVaxys common shares are listed on the Canadian Securities Exchange under the stock symbol &#34;BIOV&#34; and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
<div class="lb-trans">BioVaxys 的普通股在加拿大證券交易所上市，股票代碼為&#34;BIOV&#34;，並在法蘭克福證券交易所（FRA: 5LB）和美國 OTC 市場（OTCQB 市場）交易。有關更多信息，請訪問 www.biovaxys.com，並在 X 和 LinkedIn 上與我們聯繫。
</div>ON BEHALF OF THE BOARD
<div class="lb-trans">代表董事會
</div>Signed &#34; James Passin&#34;
<div class="lb-trans">簽名 &#34; James Passin&#34;
</div>James Passin, Chief Executive Officer
<div class="lb-trans">James Passin，首席執行官
</div>Phone: +1 740 358 0555
<div class="lb-trans">電話：+1 740 358 0555
</div>Cautionary Statements Regarding Forward Looking Information
<div class="lb-trans">關於前瞻性信息的警示聲明
</div>This news release includes certain &#34;forward-looking information&#34; and &#34;forward-looking statements&#34; (collectively &#34; forward-looking statements&#34;) within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the filing of the Required Filings by March 30, 2025 and the Company's ability to comply with the provision of the alternative information guidelines described by NP 12-203, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as &#34;expects&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;potential&#34;, &#34;possible&#34;, and similar expressions, or statements that events, conditions, or results &#34;will&#34;, &#34;may&#34;, &#34;could&#34;, or &#34;should&#34; occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
<div class="lb-trans">本新聞稿包含某些&#34;前瞻性信息&#34;和&#34;前瞻性聲明&#34;（統稱為&#34; 前瞻性聲明&#34;），符合適用證券立法的定義。除歷史事實外，本文中包含的所有聲明，包括但不限於與所需文件在 2025 年 3 月 30 日之前提交以及公司遵守 NP 12-203 所述替代信息指引的能力相關的聲明，均為前瞻性聲明。前瞻性聲明通常但不總是通過諸如&#34;預計&#34;、&#34;預期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;估計&#34;、&#34;潛在&#34;、&#34;可能&#34;等詞語或聲明事件、條件或結果&#34;將&#34;、&#34;可能&#34;、&#34;可以&#34;或&#34;應該&#34;發生或實現來識別。不能保證這些聲明將被證明是準確的，實際結果和未來事件可能與這些前瞻性聲明中表達或暗示的結果有實質性差異。
</div>These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the risk that the Company may not be able to file the Required Filings by March 30, 2025. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
<div class="lb-trans">這些前瞻性聲明反映了聲明發布時的信念、觀點和預測，並基於多個假設和估計，主要假設是 BioVaxys 將在疫苗的開發和測試中取得成功，儘管 BioVaxys 認為這些假設是合理的，但本質上仍然受到重大商業、經濟、競爭、政治和社會不確定性及偶發事件的影響。許多已知和未知的因素可能導致實際結果、表現或成就與這些前瞻性聲明所表達或暗示的結果、表現或成就存在重大差異，相關方已基於或與這些因素相關的許多假設和估計作出判斷。這些因素包括但不限於，公司可能無法在 2025 年 3 月 30 日之前提交所需文件的風險。BioVaxys 不承擔任何更新前瞻性聲明的義務，包括信念、觀點、預測或其他因素的變化，除非適用的證券法律要求。
</div>The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this press release and does not accept responsibility for the adequacy or accuracy of this release.
<div class="lb-trans">加拿大證券交易所未審查、批准或否決本新聞稿的內容，並不對本稿的充分性或準確性承擔責任。
</div>Logo: https://mma.prnewswire.com/media/2415135/5196269/BioVaxys_Technology_Corp_Logo.jpg
<div class="lb-trans">Logo: https://mma.prnewswire.com/media/2415135/5196269/BioVaxys_Technology_Corp_Logo.jpg
</div>SOURCE BioVaxys Technology Corp.
<div class="lb-trans">來源：BioVaxys Technology Corp.
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzAzJk5ld3NJdGVtSWQ9TE4zMjM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMDMxODE5UFJfTkVXU19VU1BSX19fX19MTjMyMzQ4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN32348&amp;Transmission_Id=202503031819PR_NEWS_USPR_____LN32348&amp;DateId=20250303"/>

BioVaxys Technology Corp. 獲得管理層停止交易令